Does Insurance Cover GLP-1 Shots for Weight Loss?

The 2026 coverage landscape, plan type by plan type

"Excluded" means the plan document rules out weight loss drugs as a category; no prior authorization, however well written, overrides a category exclusion.

The ten-minute plan check that saves months

Before any appointment, answer one question: does your plan cover the category at all? The sequence:

• Open your plan's drug formulary, the searchable list on your insurer's portal, and search "Wegovy" and "Zepbound" by name.
• Listed with a tier number: covered in principle; note the tier and the letters "PA", prior authorization, next to it.
• Listed as "excluded" or absent alongside an exclusion of "weight loss agents": category exclusion; skip straight to the cash plan B below rather than fighting a wall.
• Ambiguous: call the member line and ask specifically whether the plan covers "anti-obesity medications" and what the PA criteria are.

This filter matters because prior authorization effort only pays off on plans where coverage exists. Fighting a category exclusion wastes the months better spent at $99–$499 cash prices, per the full price overview.

For employer plans, add one step the formulary cannot show: the benefits team. Coverage of anti-obesity medication is an annual employer election, and a written question to HR, is it covered, and if not, has adding it been considered, both gets a definitive answer and registers demand. Member requests are among the inputs that move these annual decisions, which makes the email worth sending even in a year when the answer is no.

Prior authorization: what approvals actually contain

Where coverage exists, PA is the gate, and approved files share a pattern. Insurers want the FDA criteria documented: BMI of 30 or higher, or 27-plus with a weight-related condition such as hypertension, high cholesterol, or sleep apnea, in the chart, with numbers and dates. Many also require documented previous weight loss attempts, a diet or lifestyle program, sometimes other medications, and some ask for baseline labs.

A strong medical necessity letter from your provider states the diagnosis codes, the BMI history, the comorbidities by name, prior attempts and their outcomes, and the specific drug and dose requested. Denials are commonly procedural, a missing data point rather than a policy verdict, and first-level appeals with completed documentation frequently succeed. Persistence is a strategy: the difference between giving up at denial one and appealing properly is often $5,000-plus a year.

Keep a paper trail from the first call: reference numbers, representative names, and every denial letter in writing. Appeals are won on documentation, and external review, the step beyond the insurer's internal process, exists in every state for claims that survive that far.

Medicare and the two side doors

Medicare's rule is categorical: no coverage for drugs prescribed for weight loss alone. The side doors are the bonus indications. Wegovy's cardiovascular risk reduction approval means Medicare patients with established cardiovascular disease and elevated weight can be covered on-label, with the claim built on the cardiac history. Zepbound's obstructive sleep apnea approval does the same for patients with a documented sleep study.

These are not loopholes; they are approved indications with their own PA logic, detailed on the brand side in the Wegovy and Zepbound cost guides. For patients who genuinely carry those diagnoses, the coverage conversation changes completely, and the drug choice between the two often follows the diagnosis rather than preference.

Plan B: the cash market, priced

If the answer is a hard no, the 2026 cash market is far better than it was: compounded semaglutide ≈ $99–$299, compounded tirzepatide ≈ $199–$449, brand Wegovy or Ozempic $499 flat via NovoCare, brand Zepbound vials $349–$499 via LillyDirect. Two softeners apply: prescribed GLP-1s are generally HSA/FSA eligible, an effective 20–35% discount in pre-tax dollars, and plans change annually, so a no this year is worth rechecking at open enrollment, especially as employers keep adding the benefit.

Structure the fallback deliberately rather than defaulting into it. Decide the monthly number you can sustain for at least a year, since trial results accrued over 68 to 72 weeks; pick the channel that fits it, compounded at the low end, manufacturer direct in the middle; and diarize the next open enrollment as the moment to re-run the coverage check. Treating cash-pay as a bridge with a review date, not a permanent identity, is what keeps the copay option alive.

Eligibility runs through a licensed provider on the same BMI criteria insurers use; the assessment is the quick first pass. To see what the telehealth programs currently charge, compare cash-pay GLP-1 pricing here.